Increased proliferation and chemosensitivity of human mesenchymal stromal cells expressing fusion yeast cytosine deaminase

Stem Cell Research

Volumn 8, Issue 2, 2012, Pages 247-258

  Kucerova, Lucia ^a   Poturnajova, Martina ^a   Tyciakova, Silvia ^a   Matuskova, Miroslava ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSINE; CYTOSINE DEAMINASE; ENHANCED GREEN FLUORESCENT PROTEIN; FLUOROURACIL; HYBRID PROTEIN; RETROVIRUS VECTOR; URACIL PHOSPHORIBOSYLTRANSFERASE;

ADIPOSE TISSUE CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL EXPANSION; CELL PROLIFERATION; CHEMOSENSITIVITY; CHEMOSENSITIZATION; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STROMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TRANSGENE; TUMOR CELL DESTRUCTION; VIRAL GENE DELIVERY SYSTEM; YEAST;

ADIPOSE TISSUE; APOPTOSIS; AZACITIDINE; BREAST NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CYTARABINE; CYTOSINE DEAMINASE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; GENETIC ENGINEERING; GREEN FLUORESCENT PROTEINS; HUMANS; MESENCHYMAL STROMAL CELLS; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84855280129     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2011.11.006     Document Type: Article

References (45)

1. Bernardo M.E., Locatelli F., Fibbe W.E. Mesenchymal stromal cells. Ann. N. Y. Acad. Sci. 2009, 1176:101-117.
2. Brooke G., Cook M., Blair C., Han R., Heazlewood C., Jones B., Kambouris M., Kollar K., McTaggart S., Pelekanos R., Rice A., Rossetti T., Atkinson K. Therapeutic applications of mesenchymal stromal cells. Semin. Cell Dev. Biol. 2007, 18:846-858.
3. Caimi P.F., Reese J., Lee Z., Lazarus H.M. Emerging therapeutic approaches for multipotent mesenchymal stromal cells. Curr. Opin. Hematol. 2010, 17:505-513.
4. Cavarretta I.T., Altanerova V., Matuskova M., Kucerova L., Culig Z., Altaner C. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol. Ther. 2010, 18:223-231.
5. Dalhoff A. Pleiotropic actions of aminoglycosides. Antibiot. Chemother. 1987, 39:182-204.
6. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
7. Frank N.Y., Pendse S.S., Lapchak P.H., Margaryan A., Shlain D., Doeing C., Sayegh M.H., Frank M.H. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J. Biol. Chem. 2003, 278:47156-47165.
8. Fritz V., Jorgensen C. Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr. Stem Cell Res. Ther. 2008, 3:32-42.
9. Gnecchi M., Melo L.G. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Meth. Mol. Biol. 2009, 482:281-294.
10. Hlavaty J., Hlubinova K., Altanerova V., Liska J., Altaner C. Treatment of rat gliomas with recombinant retrovirus harboring Herpes simplex virus thymidine kinase suicide gene. Neoplasma 1997, 44:342-347.
11. Hung S.C., Deng W.P., Yang W.K., Liu R.S., Lee C.C., Su T.C., Lin R.J., Yang D.M., Chang C.W., Chen W.H., Wei H.J., Gelovani J.G. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin. Cancer Res. 2005, 11:7749-7756.
12. Hung C.J., Yao C.L., Cheng F.C., Wu M.L., Wang T.H., Hwang S.M. Establishment of immortalized mesenchymal stromal cells with red fluorescence protein expression for in vivo transplantation and tracing in the rat model with traumatic brain injury. Cytotherapy 2010, 12:455-465.
13. Kallifatidis G., Beckermann B.M., Groth A., Schubert M., Apel A., Khamidjanov A., Ryschich E., Wenger T., Wagner W., Diehlmann A., Saffrich R., Krause U., Eckstein V., Mattern J., Chai M., Schutz G., Ho A.D., Gebhard M.M., Buchler M.W., Friess H., Buchler P., Herr I. Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer. Cancer Gene Ther. 2008, 15:231-240.
14. Kidd S., Spaeth E., Dembinski J.L., Dietrich M., Watson K., Klopp A., Battula V.L., Weil M., Andreeff M., Marini F.C. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009, 27:2614-2623.
15. Klopp A.H., Gupta A., Spaeth E., Andreeff M., Marini F. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem Cells 2011, 29:11-19.
16. Kucerova L., Altanerova V., Matuskova M., Tyciakova S., Altaner C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007, 67:6304-6313.
17. Kucerova L., Matuskova M., Pastorakova A., Tyciakova S., Jakubikova J., Bohovic R., Altanerova V., Altaner C. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J. Gene Med. 2008, 10:1071-1082.
18. Kucerova L., Matuskova M., Hlubinova K., Altanerova V., Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol. Cancer 2010, 9:129.
19. Kucerova L., Kovacovicova M., Polak S., Bohac M., Fedeles J., Palencar D., Matuskova M. Interaction of human adipose tissue-derived mesenchymal stromal cells with breast cancer cells. Neoplasma 2011, 58:361-370.
20. Kumar S., Chanda D., Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther. 2008, 15:711-715.
21. Lee K., Majumdar M.K., Buyaner D., Hendricks J.K., Pittenger M.F., Mosca J.D. Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol. Ther. 2001, 3:857-866.
22. Li J., Law H.K., Lau Y.L., Chan G.C. Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br. J. Haematol. 2004, 127:326-334.
23. Liang W., Xia H., Li J., Zhao R.C. Human adipose tissue derived mesenchymal stem cells are resistant to several chemotherapeutic agents. Cytotechnology 2011, 63:523-530.
24. Ling X., Marini F., Konopleva M., Schober W., Shi Y., Burks J., Clise-Dwyer K., Wang R.Y., Zhang W., Yuan X., Lu H., Caldwell L., Andreeff M. Mesenchymal stem cells overexpressing IFN-beta Inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic tumor model. Cancer Microenviron. 2010, 3:83-95.
25. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3:330-338.
26. Matuskova M., Hlubinova K., Pastorakova A., Hunakova L., Altanerova V., Altaner C., Kucerova L. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett. 2010, 290:58-67.
27. Miyazaki K., Shibahara T., Sato D., Uchida K., Suzuki H., Matsui H., Yanaka A., Nakahara A., Matsuzaki Y. Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J. Gastroenterol. 2006, 41:140-150.
28. Momin E.N., Vela G., Zaidi H.A., Quinones-Hinojosa A. The oncogenic potential of mesenchymal stem cells in the treatment of cancer: directions for future research. Curr. Immunol. Rev. 2010, 6:137-148.
29. Mueller L.P., Luetzkendorf J., Mueller T., Reichelt K., Simon H., Schmoll H.J. Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells 2006, 24:2753-2765.
30. Neuhuber B., Swanger S.A., Howard L., Mackay A., Fischer I. Effects of plating density and culture time on bone marrow stromal cell characteristics. Exp. Hematol. 2008, 36:1176-1185.
31. Olivo C., Alblas J., Verweij V., Van Zonneveld A.J., Dhert W.J., Martens A.C. In vivo bioluminescence imaging study to monitor ectopic bone formation by luciferase gene marked mesenchymal stem cells. J. Orthop. Res. 2008, 26:901-909.
32. Piccoli C., Scrima R., Ripoli M., Di Ianni M., Del Papa B., D'Aprile A., Quarato G., Martelli M.P., Servillo G., Ligas C., Boffoli D., Tabilio A., Capitanio N. Transformation by retroviral vectors of bone marrow-derived mesenchymal cells induces mitochondria-dependent cAMP-sensitive reactive oxygen species production. Stem Cells 2008, 26:2843-2854.
33. Ronsyn M.W., Daans J., Spaepen G., Chatterjee S., Vermeulen K., D'Haese P., Van Tendeloo V.F., Van Marck E., Ysebaert D., Berneman Z.N., Jorens P.G., Ponsaerts P. Plasmid-based genetic modification of human bone marrow-derived stromal cells: analysis of cell survival and transgene expression after transplantation in rat spinal cord. BMC Biotechnol. 2007, 7:90.
34. Salem H.K., Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010, 28:585-596.
35. Shakhbazau A.V., Sevyaryn I.N., Goncharova N.V., Grinev V.V., Kosmacheva S.M., Potapnev M.P. Viral vectors for stable transduction of human mesenchymal stem cells: systems based on adeno-associated viruses and lentiviruses. Bull. Exp. Biol. Med. 2008, 146:531-533.
36. Spaeth E., Klopp A., Dembinski J., Andreeff M., Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008, 15:730-738.
37. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
38. Tallone T., Realini C., Bohmler A., Kornfeld C., Vassalli G., Moccetti T., Bardelli S., Soldati G. Adult human adipose tissue contains several types of multipotent cells. J. Cardiovasc. Transl. Res. 2011, 4:200-210.
39. Thirion P., Michiels S., Pignon J.P., Buyse M., Braud A.C., Carlson R.W., O'Connell M., Sargent P., Piedbois P. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. 2004, 22:3766-3775.
40. Toi M., Atiqur Rahman M., Bando H., Chow L.W. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol. 2005, 6:158-166.
41. Vilalta M., Degano I.R., Bago J., Aguilar E., Gambhir S.S., Rubio N., Blanco J. Human adipose tissue-derived mesenchymal stromal cells as vehicles for tumor bystander effect: a model based on bioluminescence imaging. Gene Ther. 2009, 16:547-557.
42. Walko C.M., Lindley C. Capecitabine: a review. Clin. Ther. 2005, 27:23-44.
43. Wang H., Chen X. Imaging mesenchymal stem cell migration and the implications for stem cell-based cancer therapies. Future Oncol. 2008, 4:623-628.
44. Wright G.D., Thompson P.R. Aminoglycoside phosphotransferases: proteins, structure, and mechanism. Front. Biosci. 1999, 4:D9-D21.
45. Zhao F.J., Zhang S., Yu Z.M., Xia S.J., Li H. Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer. Prostate Cancer Prostatic Dis. 2009, 12:166-171.